Table 3.
Network meta‐analysis of PFS in HRD positive patients.
| Niraparib | ||
|---|---|---|
| 1.2 (0.70, 2.0) | Rucaparib | |
| 0.38 (0.24, 0.60) | 0.32 (0.24, 0.42) | Placebo |
Results in each cell represent the pooled HR and its 95% CrI. The estimates are located at the crossing between the column‐defining treatment and row‐defining treatment. An HR lower than one favors the column‐defining treatment. The significant results are presented in bold.